» Articles » PMID: 33584523

C-Terminal-Pro-Endothelin-1 Adds Incremental Prognostic Value for Risk Stratification After Ischemic Stroke

Overview
Journal Front Neurol
Specialty Neurology
Date 2021 Feb 15
PMID 33584523
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Endothelins have shown to play a role in the pathophysiology of ischemic stroke. We aimed at evaluating the incremental prognostic value of C-terminal-pro-endothelin-1 (CT-pro-ET-1) in a well-described cohort of acute stroke patients. We performed serial measurements of CT-pro-ET-1 in 361 consecutively enrolled ischemic stroke patients and assessed functional outcome and mortality after 90 days. As we found peak levels of CT-pro-ET-1 and the most prominent association with mortality on day 1 after admission ( = 312), we focused on this time point for further outcome analyses. We calculated logistic regression and cox proportional hazards models to estimate the association of CT-pro-ET-1 with our outcome measures after adjusting for demographic and clinical risk factors. To evaluate the incremental value of CT-pro-ET-1, we calculated the area under the receiver operating characteristics (AUC) curve and the continuous net reclassification index (cNRI) comparing the model with and without the biomarker CT-pro-ET-1. In the univariate analysis CT-pro-ET-1 with a peak on day 1 after admission was associated with unfavorable outcome with an OR of 1.32 (95% CI, 1.16-1.51, < 0.001) and with mortality with a HR of 1.45 (95% CI, 1.29-1.63, < 0.001). After adjusting, CT-pro-ET-1 remained an independent predictor of mortality with an adjusted HR of 1.50 (95% CI, 1.29-1.74, < 0.001), but not for functional outcome. Adding CT-pro-ET-1 to the cox-regression model for mortality, the discriminatory accuracy improved from 0.89 (95% CI, 0.84-0.94) to 0.92 (95% CI, 0.88-0.96) < 0.001, and the cNRI was 0.72 (95% CI, 0.17-1.13). CT-pro-ET-1 with a peak level on day 1 was an independent predictor of mortality adding incremental prognostic value beyond traditional risk factors.

Citing Articles

Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity.

Boutin G, Yuzugulen J, Pranjol M J Mol Cell Cardiol Plus. 2025; 6():100053.

PMID: 39802623 PMC: 11708141. DOI: 10.1016/j.jmccpl.2023.100053.


Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study.

Then C, Sujana C, Herder C, Then H, Heier M, Meisinger C Vasc Health Risk Manag. 2022; 18:335-346.

PMID: 35535305 PMC: 9078871. DOI: 10.2147/VHRM.S363814.

References
1.
Struck J, Morgenthaler N, Bergmann A . Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides. 2005; 26(12):2482-6. DOI: 10.1016/j.peptides.2005.05.010. View

2.
Haapaniemi E, Tatlisumak T, Hamel K, Soinne L, Lanni C, Opgenorth T . Plasma endothelin-1 levels neither increase nor correlate with neurological scores, stroke risk factors, or outcome in patients with ischemic stroke. Stroke. 2000; 31(3):720-5. DOI: 10.1161/01.str.31.3.720. View

3.
Unic A, derek L, Hodak N, Marijancevic D, ceprnja M, Serdar T . Endothelins -- clinical perspectives. Biochem Med (Zagreb). 2012; 21(3):231-42. DOI: 10.11613/bm.2011.032. View

4.
Hatano S . Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976; 54(5):541-53. PMC: 2366492. View

5.
Sims J, Gharai L, Schaefer P, Vangel M, Rosenthal E, Lev M . ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology. 2009; 72(24):2104-10. PMC: 2697964. DOI: 10.1212/WNL.0b013e3181aa5329. View